Abstract
This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than
| Original language | English |
|---|---|
| Pages (from-to) | 127-132 |
| Number of pages | 6 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 155 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2016 |
Fingerprint
Keywords
- Breast cancer
- Disease-free survival
- HER2+
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval : the HERA trial experience. / Metzger-Filho, Otto; De Azambuja, E.; Procter, Marion; Krieguer, Magalie; Smith, Ian; Baselga, Jose; Cameron, David; Untch, Michael; Jackisch, Christian; Bell, Richard; Gianni, Luca; Goldhirsch, Aron; Piccart, Martine; Gelber, R. D.
In: Breast Cancer Research and Treatment, Vol. 155, No. 1, 01.01.2016, p. 127-132.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval
T2 - the HERA trial experience
AU - Metzger-Filho, Otto
AU - De Azambuja, E.
AU - Procter, Marion
AU - Krieguer, Magalie
AU - Smith, Ian
AU - Baselga, Jose
AU - Cameron, David
AU - Untch, Michael
AU - Jackisch, Christian
AU - Bell, Richard
AU - Gianni, Luca
AU - Goldhirsch, Aron
AU - Piccart, Martine
AU - Gelber, R. D.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than
AB - This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than
KW - Breast cancer
KW - Disease-free survival
KW - HER2+
UR - http://www.scopus.com/inward/record.url?scp=84953357758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953357758&partnerID=8YFLogxK
U2 - 10.1007/s10549-015-3656-0
DO - 10.1007/s10549-015-3656-0
M3 - Article
VL - 155
SP - 127
EP - 132
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 1
ER -